Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa F-P Ng

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) SeverityBarnaby E Young, Sean W X Ong, Lisa F P Ng, et al.
The Journal of Infectious Diseases|November 23, 2023
Variant-Specific IgA Protects Against Omicron InfectionYun Shan Goh, Siew-Wai Fong, Pei Xiang Hor, et al.
Antiviral Research|June 10, 2017
Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus NetworkMatthew T Aliota, Leda Bassit, Shelton S Bradrick, et al.
Lancet (London, England)|August 22, 2020
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort studyBarnaby E Young, Siew-Wai Fong, Yi-Hao Chan, et al.
Frontiers in Immunology|June 19, 2025
Novel NUDCD1 gene variant predisposes to severe COVID-19 disease in Asians through modulation of antiviral DHX15- and MAVS-mediated signallingAseervatham Anusha Amali, Douglas Jie Wen Tay, Yiqi Seow, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Frontiers in Immunology|December 6, 2021
Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe IndividualsJackwee Lim, Kia Joo Puan, Liang Wei Wang, et al.
The Journal of Experimental Medicine|December 16, 2024
A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunityFahd Al Qureshah, Jérémie Le Pen, Nicole A de Weerd, et al.
Journal of Medical Virology|October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boostersAngeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) SeverityBarnaby E Young, Sean W X Ong, Lisa F P Ng, et al.
The Journal of Infectious Diseases|November 23, 2023
Variant-Specific IgA Protects Against Omicron InfectionYun Shan Goh, Siew-Wai Fong, Pei Xiang Hor, et al.
Antiviral Research|June 10, 2017
Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus NetworkMatthew T Aliota, Leda Bassit, Shelton S Bradrick, et al.
Lancet (London, England)|August 22, 2020
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort studyBarnaby E Young, Siew-Wai Fong, Yi-Hao Chan, et al.
Frontiers in Immunology|June 19, 2025
Novel NUDCD1 gene variant predisposes to severe COVID-19 disease in Asians through modulation of antiviral DHX15- and MAVS-mediated signallingAseervatham Anusha Amali, Douglas Jie Wen Tay, Yiqi Seow, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Frontiers in Immunology|December 6, 2021
Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe IndividualsJackwee Lim, Kia Joo Puan, Liang Wei Wang, et al.
The Journal of Experimental Medicine|December 16, 2024
A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunityFahd Al Qureshah, Jérémie Le Pen, Nicole A de Weerd, et al.
Journal of Medical Virology|October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boostersAngeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Pageof 17